LFT Ordering Behavior Payam Parvinchiha DSR 2. Guidelines No guidelines for ordering of LFT Should not be a screening test for liver disease population-based.

Slides:



Advertisements
Similar presentations
Evaluation of Abnormal Liver Function Tests Dr Deb Datta Consultant Gastroenterolgist.
Advertisements

Update in Liver Disease SGNA April 4, 2014 Outline Interpretation of elevated liver chemistries Fatty liver disease Hepatitis B Hepatitis C.
Is the BMI a Relic of the Past? Wang-Sheng Lee School of Accounting, Economics and Finance Deakin University (joint work with David Johnston, Monash University)
Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,
Predictors of elevated transaminase levels in patients with central obesity V. Papastergiou, G. Ntetskas, L. Skorda, F. Lambrianou, K. Roufas, E. Asonitis,
Liver Function Tests (LFTs)
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD Featured Article: Jessica Bazick,
BMI: Body Mass Index. The term BMI is often used when discussing the obesity epidemic, but what is BMI?
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
Approach to medical liver biopsies Dr Behrang Mozayani Consultant Histopathologist Southmead hospital Bristol.
Long term outcome of patients with autoimmune hepatitis receiving mycophenolate mofetil (MMF) as first line treatment Kalliopi Zachou1, Nikolaos Gatselis1,
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Deranged LFTs Pathways A H Mohsen Dr A H Mohsen MD (KCL), MRCP, DTM&H Consultant Gastroenterologist.
Eleni Galani Medical Oncologist
Hepatitis C Education & Awareness. Women In Government Women In Government Foundation, Inc. is a national, non-profit, non-partisan organization of women.
THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.
Liver Pathology, CASE 2 53 year-old with chronic alcohol and drug abuse who has been in numerous rehabilitation facilities in the past now presents with.
IL FEGATO IL PANCREAS…..ed I loro segnali
Update from NIH/HHS: Healthy People 2020 Nutrition and Weight Status Focus Area Van S. Hubbard, M.D., Ph.D. Rear Admiral, U.S. Public Health Service NIH.
Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.
Shellie Ray Auburn University. Obesity is one of the most challenging health crises the country has ever faced. Second only to cigarette smoking, obesity.
Dealing with NASH “mildly abnormal LFTs”. Liver disease is a national epidemic.
Upon completion of this lesson, you will be able to: Identify different diagnostic procedures for breast cancer screening Describe different diagnostic.
LIVER HEALTH an integral part of CF gastrointestinal care Zachary M Sellers, MD, PhD Fellow Pediatric Gastroenterology, Hepatology, and Nutrition Stanford.
Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.
Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation Ki Tae Yoon, Sun Min Lim,Jun Yong.
The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.
Jun Yu,1,2 Joseph Jao-Yiu Sung,1,2 Henry Lik-Yuen Chan1,2
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Date of download: 6/29/2016 From: Predicting Future Functional Status for Seriously Ill Hospitalized Adults: The SUPPORT Prognostic Model Ann Intern Med.
© McGraw-Hill Higher Education. All Rights Reserved Body Composition Chapter Six.
Date of download: 7/3/2016 From: Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Ann Intern Med. 2000;133(4): doi: /
Date of download: 7/5/2016 From: Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:
F. 정 회 훈 Am J Gastroenterol 2012;107:46-52 Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy:
Budesonide induces remission more effectively than Prednisone in a controlled trial of patients with Autoimmune Hepatitis GASTROENTEROLOGY 2010;139:1198–1206.
Liver Function Tests (LFTs)
Diagnostic Pathway for Chronic Liver Disease
How to Calculate Your Body Mass Index (BMI)
Liver Function Tests (LFTs)
Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity  Paula Walle, Markus Takkunen, Ville Männistö, Maija Vaittinen,
Volume 32, Issue 2, Pages (February 2000)
Evaluation of liver function in the inpatient setting: CMP vs BMP
Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients
Asymptomatic Abnormal LFTs NHS Lothian guideline
Underwriting Screening Liver Test Abnormalities:
Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2
Additional file 2 Total HCC cases N=39
BMI: Body Mass Index.
Dietary Guideline #2 Weight Management
Chronic viral hepatitis type B with “ground glass” cells
Alcoholic cirrhosis and acute alcoholic fatty liver with cholestasis
Non-alcoholic steatohepatitis with positive ANA
Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
Alcoholic foamy degeneration with early alcoholic cirrhosis
Figure 7 Management algorithm for patients with ACLF
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5 year open-label follow-up study Martin Gerbert,
Figure 1 Proposed algorithm for the management
Dietary Guideline #2 Weight Management
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis  Jean–François Dufour, Carl M. Oneta, Jean–Jacques.
Rohit Loomba, MD, MHSc  Clinical Gastroenterology and Hepatology 
Volume 143, Issue 2, Pages (August 2012)
Asymptomatic Abnormal LFTs NHS Lothian guideline
Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes.
Volume 69, Issue 5, Pages (November 2018)
Volume 64, Issue 6, Pages (June 2016)
Volume 140, Issue 1, Pages (January 2011)
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba  Gastroenterology 
(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.
Presentation transcript:

LFT Ordering Behavior Payam Parvinchiha DSR 2

Guidelines No guidelines for ordering of LFT Should not be a screening test for liver disease population-based survey in the United States conducted between 1999 and 2002 estimated that an abnormal ALT was present in 8.9 percent of respondents ALT level correlates with body mass index (BMI) and waist circumference, and the BMI of Americans has increased significantly over time Am J Gastroenterol. 2006;101(1):76.

Abnormal serum aminotransferase levels (ALT >2.25 SD above normal; >55 int. unit/L) were detected in 99 of 19,877 (0.5 percent) Air Force recruits beginning basic training [7]. Of these, a cause was found in only 12 (including chronic hepatitis B and C, autoimmune hepatitis, and cholelithiasis). No specific diagnosis was established in the remaining 87 patients.7 Dig Dis Sci. 1993;38(12):2145.

Most likely Dx Another study focused on 81 of 1124 patients who were referred for abnormal serum aminotransferase levels in whom a diagnosis could not be inferred noninvasively [11]. A liver biopsy revealed steatosis or steatohepatitis in the majority of patients (84 percent); six patients had fibrosis or cirrhosis, and eight had normal histologic findings.11 Am J Gastroenterol. 1999;94(10):3010.

Fluctuations Individual patients can have baseline fluctuation in serum aminotransferase levels. In a large, cross-sectional population- based study, more than 30 percent of adults with abnormal LFTS were reclassified as being normal upon retesting [14].14 Ann Intern Med. 2008;148(5):348.

False positive Normal reference values-arbitrarily determined to be 2 SD above the mean 5 percent of healthy individuals who have a single screening test will have an abnormal result (2.5 percent will have an abnormally high result). As more tests are ordered, the likelihood of a false positive test increases; a screening panel containing 20 independent tests in a patient with no disease will yield at least one abnormal result 64 percent of the time

Cost of LFT $25-$35 Hepatitis Panel: $125 RUQ Ultrasound: $125

Cross sectional Analysis All patients on Ward Teams A/B on 3/25 Admission Days, LFT on admission, # of LFT total, Hx of Liver Dx, Indication for LFT charted, New Abnormalities found, further w/u ordered

23 Patients Avg LOS: 6.5 days #LFT/Admission: 4.7 #LFT/Day of admission:.8 LFT on admission: 18/23 Hx Liver Dx: 4/23 Indications: 5/23 New Abn: 14/23 Further w/u: 6

If $25 / LFT then $20 spent / patient/day on LFT given this sample $120 per admission on LFT’s Most patient’s w/o indication for LFT’s Minimal further w/u done in this population of ts